NCT04550247View on ClinicalTrials.gov

A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France

Active, not recruitingOBSERVATIONAL
Enrollment

362

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

March 15, 2027

Study Completion Date

March 15, 2027

Conditions
Melanoma
Trial Locations (1)

59000

Local Institution, Lille

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04550247 - A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France | Biotech Hunter | Biotech Hunter